Guided anti-P2Y12 therapy in patients undergoing PCI: three systematic reviews with meta-analyses of randomized controlled trials with homogeneous design
S Birocchi, M Rocchetti, A Minardi… - Thrombosis and …, 2024 - thieme-connect.com
Background The value of guided therapy (GT) with anti-P2Y12 drugs in percutaneous
coronary intervention (PCI) is unclear. Meta-analyses lumped together randomized …
coronary intervention (PCI) is unclear. Meta-analyses lumped together randomized …
Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes
I Russo, CG Brookles, C Barale, E Melchionda… - International Journal of …, 2024 - mdpi.com
The role of antiplatelet therapy in patients with acute coronary syndromes is a moving target
with considerable novelty in the last few years. The pathophysiological basis of the treatment …
with considerable novelty in the last few years. The pathophysiological basis of the treatment …
Role of Cyp2c19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
M Rajachandran, RA Lange - Current Cardiology Reports, 2024 - Springer
Abstract Purpose of Review Identification of a reliable discriminatory test to accurately stratify
patient responses to antiplatelet therapy following coronary revascularization has become …
patient responses to antiplatelet therapy following coronary revascularization has become …
[HTML][HTML] Rationale and design for the randomized placebo-controlled double-blind trial studying the effect of single antiplatelet therapy (clopidogrel) versus dual …
ECJ Wegerif, Ç Ünlü, MI Generaal… - American Heart …, 2024 - Elsevier
Rationale Antiplatelet therapy (APT) is the standard of care after endovascular
revascularization (EVR) in patients with peripheral artery disease (PAD). APT aims to …
revascularization (EVR) in patients with peripheral artery disease (PAD). APT aims to …
Platelet-fibrin clot strength and platelet reactivity predicting cardiovascular events after percutaneous coronary interventions
O Kwon, JH Ahn, JS Koh, Y Park… - European Heart …, 2024 - academic.oup.com
Abstract Background and Aims Platelet-fibrin clot strength (PFCS) is linked to major adverse
cardiovascular event (MACE) risk. However, the association between PFCS and platelet …
cardiovascular event (MACE) risk. However, the association between PFCS and platelet …
Machine learning insights into thrombo-ischemic risks and bleeding events through platelet lysophospholipids and acylcarnitine species
T Harm, X Fu, M Frey, K Dittrich, A Brun, T Castor… - Scientific Reports, 2024 - nature.com
Coronary artery disease (CAD) often leads to adverse events resulting in significant disease
burdens. Underlying risk factors often remain inapparent prior to disease incidence and the …
burdens. Underlying risk factors often remain inapparent prior to disease incidence and the …
Perioperative platelet reactivity over time in patients undergoing vascular surgery: An observational pilot study
ART Brand Kanters, NC Roozendaal, NMJ Parr… - Plos one, 2024 - journals.plos.org
Background Despite Antiplatelet therapy (APT), cardiovascular patients undergoing
revascularisation remain at high risk for thrombotic events. Individual response to APT varies …
revascularisation remain at high risk for thrombotic events. Individual response to APT varies …
Short-versus long-term Dual AntiPlatelet Therapy for Stent-Assisted treatment of CErebral aneurysm (DAPTS ACE): a multicenter, open-label, randomized clinical trial
T Ozaki, H Yamagami, M Morimoto, T Hatano… - Journal of …, 2024 - jnis.bmj.com
Background The optimal duration of dual antiplatelet therapy (DAPT) after stent-assisted coil
embolization (SACE) for cerebral aneurysm remains uncertain. This randomized trial of short …
embolization (SACE) for cerebral aneurysm remains uncertain. This randomized trial of short …
[HTML][HTML] Differential impact of fentanyl and morphine doses on ticagrelor-induced platelet inhibition in ST-segment elevation myocardial infarction: a subgroup analysis …
Introduction Among patients with ST-segment elevation myocardial infarction (STEMI)
treated with primary percutaneous coronary intervention (PCI), intravenous fentanyl does not …
treated with primary percutaneous coronary intervention (PCI), intravenous fentanyl does not …
Smoking and outcomes following personalized antiplatelet therapy in chronic coronary syndrome patients: A substudy from the randomized PATH‐PCI trial
Y Pan, TT Wu, CJ Deng, Y Yang, XG Hou… - Clinical …, 2024 - Wiley Online Library
Background This is a sub‐analysis of the Personalized Antithrombotic Therapy for Coronary
Heart Disease after PCI (PATH‐PCI) trial in China to explore the relationship between …
Heart Disease after PCI (PATH‐PCI) trial in China to explore the relationship between …